MeSH term
Frequency | Condition_Probility | Biological Transport | 4 | 0.0 |
Estrone/*analogs & derivatives/pharmacology | 2 | 50.0 |
Humans | 223 | 0.0 |
Amino Acid Sequence | 12 | 0.0 |
Animals | 50 | 0.0 |
Blotting, Northern | 6 | 0.0 |
Carrier Proteins/*metabolism | 2 | 0.0 |
Cloning, Molecular | 10 | 0.0 |
Dose-Response Relationship, Drug | 8 | 0.0 |
Exons | 4 | 0.0 |
Female | 96 | 0.0 |
Gene Library | 3 | 0.0 |
Immunohistochemistry | 5 | 0.0 |
Male | 123 | 0.0 |
Membrane Proteins/metabolism | 2 | 0.0 |
Molecular Sequence Data | 25 | 0.0 |
Oocytes/metabolism | 4 | 2.0 |
Phylogeny | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 119 | 0.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Spermatozoa/physiology | 3 | 10.0 |
Structure-Activity Relationship | 3 | 0.0 |
Substrate Specificity | 5 | 0.0 |
Tissue Distribution | 3 | 0.0 |
Administration, Oral | 27 | 2.0 |
Anticoagulants/*administration & dosage | 11 | 26.0 |
Drug Therapy, Combination | 4 | 0.0 |
English Abstract | 27 | 0.0 |
Syndrome | 8 | 0.0 |
Time Factors | 11 | 0.0 |
Adult | 79 | 0.0 |
Aged | 41 | 0.0 |
Aged, 80 and over | 16 | 0.0 |
Anticoagulants/adverse effects/*therapeutic use | 2 | 28.0 |
Comparative Study | 35 | 0.0 |
Confidence Intervals | 2 | 0.0 |
Follow-Up Studies | 8 | 0.0 |
Hemorrhage/chemically induced | 2 | 12.0 |
International Normalized Ratio | 11 | 37.0 |
Middle Aged | 52 | 0.0 |
Case-Control Studies | 11 | 0.0 |
Drug Interactions | 4 | 0.0 |
*International Normalized Ratio | 3 | 60.0 |
*Chromosome Aberrations | 4 | 0.0 |
Cohort Studies | 4 | 0.0 |
Karyotyping | 5 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
*Sperm-Ovum Interactions | 2 | 10.0 |
International Normalized Ratio/*standards | 2 | 100.0 |
*Prothrombin Time | 5 | 25.0 |
Reference Standards | 3 | 1.0 |
Sensitivity and Specificity | 10 | 0.0 |
Microscopy, Electron | 4 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 4 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 56 | 0.0 |
Denmark | 3 | 1.0 |
Prospective Studies | 15 | 0.0 |
Prothrombin Time | 4 | 3.0 |
*Quality of Health Care | 2 | 8.0 |
Blood Coagulation/drug effects | 3 | 2.0 |
Reproducibility of Results | 4 | 0.0 |
Anticoagulants/administration & dosage/*therapeutic use | 5 | 35.0 |
Biological Markers | 3 | 0.0 |
Comorbidity | 2 | 0.0 |
Fibrin Fibrinogen Degradation Products/analysis | 2 | 1.0 |
Incidence | 4 | 0.0 |
Italy/epidemiology | 2 | 0.0 |
Predictive Value of Tests | 3 | 0.0 |
Pregnancy | 18 | 0.0 |
Recurrence | 4 | 0.0 |
Risk | 2 | 0.0 |
Risk Factors | 7 | 0.0 |
Treatment Outcome | 9 | 0.0 |
Kidney/*metabolism | 3 | 1.0 |
Longitudinal Studies | 2 | 0.0 |
Adolescent | 16 | 0.0 |
Child | 13 | 0.0 |
Child, Preschool | 4 | 0.0 |
Infant | 4 | 0.0 |
Partial Thromboplastin Time | 3 | 1.0 |
Protein C/*metabolism | 2 | 1.0 |
Retrospective Studies | 3 | 0.0 |
In Situ Hybridization, Fluorescence | 11 | 0.0 |
Oligospermia/*genetics | 5 | 10.0 |
*Sex Chromosome Aberrations | 2 | 6.0 |
Biotransformation | 3 | 0.0 |
In Vitro | 3 | 0.0 |
*Helicobacter pylori | 2 | 1.0 |
*Aneuploidy | 7 | 7.0 |
Chromosomes, Human, Pair 12 | 3 | 1.0 |
Spermatozoa/*abnormalities/*ultrastructure | 2 | 100.0 |
Anion Transport Proteins | 4 | 26.0 |
Metabolic Detoxication, Drug | 2 | 2.0 |
Chromosomes, Human, Pair 18 | 2 | 1.0 |
Chromosomes, Human, Pair 8 | 2 | 1.0 |
Diploidy | 3 | 2.0 |
Infertility, Male/*genetics | 8 | 18.0 |
*Sperm Injections, Intracytoplasmic | 3 | 18.0 |
X Chromosome | 5 | 1.0 |
Y Chromosome | 4 | 4.0 |
Genotype | 6 | 0.0 |
Reference Values | 9 | 0.0 |
Avena sativa | 2 | 66.0 |
Kinetics | 13 | 0.0 |
Lysine/blood | 2 | 66.0 |
Helicobacter pylori/*drug effects | 2 | 15.0 |
Chromatography, High Pressure Liquid | 4 | 0.0 |
Infertility, Male/*metabolism | 3 | 14.0 |
Semen/*metabolism | 3 | 16.0 |
Spermatozoa/*metabolism | 3 | 4.0 |
Embryo Transfer | 4 | 5.0 |
Semen/*physiology | 2 | 20.0 |
Sperm Count | 5 | 8.0 |
Sperm Motility | 5 | 10.0 |
Spermatozoa/*abnormalities | 2 | 100.0 |
Cell Line | 10 | 0.0 |
Kidney Tubules, Proximal/metabolism | 2 | 14.0 |
Alleles | 6 | 0.0 |
Family Health | 2 | 0.0 |
Variation (Genetics) | 3 | 0.0 |
Choroid/*pathology | 6 | 66.0 |
Cross-Sectional Studies | 3 | 0.0 |
Electroretinography | 2 | 1.0 |
*Mutation | 10 | 0.0 |
Ornithine/blood | 2 | 50.0 |
Ornithine-Oxo-Acid Transaminase/*genetics | 23 | 95.0 |
Retina/*pathology | 2 | 9.0 |
Diagnosis, Differential | 2 | 0.0 |
Multidrug Resistance-Associated Proteins | 2 | 2.0 |
Chi-Square Distribution | 3 | 0.0 |
Chronic Disease | 2 | 0.0 |
Aneuploidy | 5 | 2.0 |
Pregnancy Rate | 3 | 2.0 |
Spermatozoa/*physiology | 3 | 7.0 |
*Avena sativa | 4 | 80.0 |
Radioimmunoassay | 3 | 0.0 |
Statistics, Nonparametric | 3 | 0.0 |
Risk Assessment | 3 | 0.0 |
Spermatozoa/*ultrastructure | 2 | 28.0 |
Double-Blind Method | 2 | 0.0 |
Insulin/blood | 2 | 0.0 |
Lipoproteins, HDL Cholesterol/blood | 3 | 0.0 |
Lipoproteins, LDL Cholesterol/blood | 3 | 0.0 |
Triglycerides/blood | 5 | 0.0 |
Protein Conformation | 4 | 0.0 |
Chromosomes, Human | 2 | 3.0 |
*In Situ Hybridization, Fluorescence | 2 | 1.0 |
Prevalence | 2 | 0.0 |
Age Factors | 4 | 0.0 |
Anticoagulants/administration & dosage/adverse effects/*therapeutic use | 2 | 100.0 |
Italy | 5 | 0.0 |
Multivariate Analysis | 3 | 0.0 |
Follicle Stimulating Hormone/blood | 3 | 0.0 |
Luteinizing Hormone/blood | 3 | 0.0 |
Testosterone/blood | 2 | 0.0 |
Cattle | 3 | 0.0 |
Cell Death | 2 | 0.0 |
Cells, Cultured | 15 | 0.0 |
Drug Synergism | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Base Sequence | 28 | 0.0 |
DNA Mutational Analysis | 4 | 0.0 |
Heterozygote | 4 | 0.0 |
Mutation | 7 | 0.0 |
Phenotype | 3 | 0.0 |
Point Mutation | 2 | 0.0 |
Mice | 17 | 0.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Plasmids | 3 | 0.0 |
DNA/analysis | 3 | 0.0 |
Fertilization in Vitro/*methods | 5 | 19.0 |
Microinjections | 4 | 1.0 |
Semen/*chemistry | 3 | 11.0 |
Catalysis | 2 | 0.0 |
Gene Expression | 4 | 0.0 |
Mutagenicity Tests | 2 | 1.0 |
Mutagens/*toxicity | 2 | 1.0 |
Infant, Newborn | 5 | 0.0 |
*Translocation, Genetic | 6 | 0.0 |
Cytoplasm | 3 | 4.0 |
*Fertilization in Vitro | 4 | 3.0 |
*X Chromosome | 10 | 1.0 |
*Y Chromosome | 3 | 2.0 |
Sex Factors | 4 | 0.0 |
Anticoagulants/*administration & dosage/*adverse effects | 2 | 100.0 |
Genetic Screening | 2 | 0.0 |
Biological Availability | 2 | 0.0 |
Hamsters | 15 | 0.0 |
Anticoagulants/*administration & dosage/adverse effects | 2 | 100.0 |
Drug Administration Schedule | 3 | 0.0 |
Drug Monitoring | 2 | 4.0 |
Phenprocoumon/*administration & dosage | 3 | 75.0 |
Anticoagulants/*therapeutic use | 4 | 8.0 |
Arginine | 2 | 2.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Polymerase Chain Reaction | 12 | 0.0 |
Ornithine-Oxo-Acid Transaminase/metabolism | 3 | 100.0 |
RNA, Messenger/metabolism | 5 | 0.0 |
Chromosome Banding | 3 | 0.0 |
Pregnancy Outcome | 4 | 1.0 |
*Fertilization in Vitro/methods | 2 | 50.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Abortion, Spontaneous | 2 | 7.0 |
*Pregnancy Outcome | 2 | 3.0 |
DNA Primers/chemistry | 2 | 0.0 |
Gene Expression Regulation, Enzymologic | 4 | 0.0 |
Transfection | 4 | 0.0 |
Blotting, Western | 4 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Binding Sites | 3 | 0.0 |
Crystallography, X-Ray | 2 | 0.0 |
Keratin/metabolism | 2 | 1.0 |
Peptide Fragments/*analysis | 2 | 4.0 |
Prothrombin/*analysis | 2 | 6.0 |
Bread | 2 | 50.0 |
Breath Tests | 2 | 2.0 |
Dietary Fiber/*metabolism | 2 | 40.0 |
Triticum | 2 | 25.0 |
Gene Therapy/*methods | 2 | 0.0 |
Genetic Vectors | 3 | 0.0 |
Keratinocytes/*metabolism | 2 | 2.0 |
Ornithine/*metabolism | 3 | 75.0 |
*Gene Transfer Techniques | 3 | 0.0 |
*Genetic Vectors | 2 | 0.0 |
Models, Molecular | 2 | 0.0 |
*Chromosomes, Human, Pair 18 | 3 | 2.0 |
Xenopus laevis | 2 | 0.0 |
*Chromosome Deletion | 4 | 0.0 |
Chromosomes, Human, Y/*genetics | 2 | 11.0 |
Research Design | 2 | 2.0 |
Chemiluminescent Measurements | 2 | 1.0 |
Semen/*enzymology | 2 | 10.0 |
Rats | 8 | 0.0 |
Sequence Alignment | 3 | 0.0 |
Species Specificity | 2 | 0.0 |
Gyrate Atrophy/*enzymology/*genetics | 2 | 100.0 |
Ornithine-Oxo-Acid Transaminase/deficiency/*genetics | 8 | 100.0 |
Sequence Deletion | 2 | 0.0 |
Atrophy | 7 | 4.0 |
Ornithine/metabolism | 2 | 66.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Mitochondria/enzymology | 2 | 1.0 |
Prognosis | 8 | 0.0 |
Genome, Viral | 2 | 1.0 |
Repetitive Sequences, Nucleic Acid | 3 | 0.0 |
4-Aminobenzoic Acid/metabolism | 2 | 15.0 |
Acetylation | 5 | 0.0 |
Bladder/*metabolism | 3 | 23.0 |
Carcinogens/*metabolism | 2 | 2.0 |
Biological Transport/drug effects | 2 | 0.0 |
Propionates/pharmacology | 2 | 25.0 |
Quinolines/pharmacology | 2 | 9.0 |
Sperm-Ovum Interactions/*physiology | 2 | 10.0 |
DNA Primers | 3 | 0.0 |
Retina/pathology | 4 | 11.0 |
Genes, Structural | 5 | 0.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
CHO Cells | 4 | 0.0 |
Cricetulus | 6 | 1.0 |
Fibroblasts/enzymology | 6 | 3.0 |
Ornithine-Oxo-Acid Transaminase/genetics | 5 | 71.0 |
Cholesterol/blood | 4 | 0.0 |
Hypercholesterolemia/*diet therapy | 2 | 66.0 |
Insulin/*blood | 2 | 1.0 |
Chromosome Mapping | 8 | 0.0 |
Moloney murine leukemia virus/*genetics | 2 | 7.0 |
*Transfection | 2 | 0.0 |
Pedigree | 6 | 0.0 |
Oligospermia/*drug therapy | 2 | 66.0 |
Sarcoma, Synovial/*genetics | 3 | 20.0 |
Blood Glucose/*metabolism | 2 | 0.0 |
*Cereals | 6 | 60.0 |
*Dietary Fiber | 3 | 37.0 |
Chromosomes, Human, Pair 18/*ultrastructure | 2 | 20.0 |
Soft Tissue Neoplasms/*genetics | 2 | 7.0 |
X Chromosome/*ultrastructure | 3 | 12.0 |
Pilot Projects | 2 | 0.0 |
Acetyltransferases/*metabolism | 3 | 3.0 |
Amino Acid Metabolism, Inborn Errors/*complications | 2 | 66.0 |
Ornithine-Oxo-Acid Transaminase/deficiency | 2 | 100.0 |
Blotting, Southern | 10 | 0.0 |
Hybrid Cells | 9 | 0.0 |
*Chromosomes, Human, Pair 10 | 6 | 3.0 |
Pseudogenes | 2 | 1.0 |
Prothrombin/analysis | 2 | 2.0 |
*Genes, Structural | 4 | 0.0 |
Genome, Human | 2 | 0.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Transcription, Genetic | 3 | 0.0 |
Cytosol/enzymology | 2 | 1.0 |
DNA/metabolism | 4 | 0.0 |
Restriction Mapping | 5 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Tumor Cells, Cultured | 2 | 0.0 |
Genetic Markers | 5 | 0.0 |
Cytosol/metabolism | 3 | 0.0 |
Epithelium/metabolism | 2 | 0.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Triiodothyronine/pharmacology | 2 | 4.0 |
Oligospermia/metabolism | 2 | 18.0 |
Blood Glucose/analysis | 2 | 0.0 |
DNA Probes | 3 | 0.0 |
*Linkage (Genetics) | 2 | 0.0 |
Lod Score | 3 | 0.0 |
Polymorphism, Restriction Fragment Length | 5 | 0.0 |
Retina/*abnormalities | 2 | 28.0 |
DNA | 8 | 0.0 |
Gyrate Atrophy/*genetics | 3 | 100.0 |
*RNA Splicing | 2 | 0.0 |
Mice, Nude | 2 | 0.0 |
Neoplasm Transplantation | 2 | 0.0 |
Gyrate Atrophy/*enzymology/genetics | 2 | 100.0 |
Ornithine-Oxo-Acid Transaminase/*genetics/metabolism | 5 | 100.0 |
Cholesterol/*blood | 2 | 0.0 |
Cholesterol, Dietary/administration & dosage | 2 | 7.0 |
Immunoblotting | 2 | 0.0 |
*Chromosome Mapping | 5 | 0.0 |
DNA Restriction Enzymes | 2 | 0.0 |
Mice, Inbred Strains | 2 | 0.0 |
DNA/genetics | 7 | 0.0 |
Fibrin Fibrinogen Degradation Products/*analysis | 2 | 4.0 |
Warfarin/administration & dosage/therapeutic use | 2 | 66.0 |
*Evolution | 2 | 1.0 |
Nucleic Acid Hybridization | 5 | 0.0 |
*Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Rabbits | 2 | 0.0 |
Linkage (Genetics) | 2 | 0.0 |
Kidney/enzymology | 2 | 1.0 |
Liver/enzymology | 4 | 0.0 |
Gastrin-Releasing Peptide | 2 | 2.0 |
Peptides/metabolism | 2 | 0.0 |
Phosphopyruvate Hydratase/metabolism | 2 | 3.0 |
Transaminases/*genetics | 19 | 61.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Transaminases/*deficiency | 2 | 100.0 |
*Cloning, Molecular | 2 | 0.0 |
RNA, Messenger/*genetics | 2 | 0.0 |
*Polymorphism, Genetic | 3 | 0.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Retinal Degeneration/enzymology/*genetics | 4 | 57.0 |
Uveal Diseases/enzymology/genetics | 3 | 100.0 |
Retinal Degeneration/*genetics | 4 | 10.0 |
Uveal Diseases/*genetics | 2 | 66.0 |
*Choroid | 4 | 100.0 |
Thromboembolism/prevention & control | 2 | 50.0 |
Skin/metabolism | 2 | 1.0 |
Algorithms | 2 | 0.0 |
Ornithine-Oxo-Acid Transaminase/*metabolism | 2 | 100.0 |
Transaminases/*metabolism | 2 | 33.0 |
Probability | 2 | 0.0 |
Severity of Illness Index | 3 | 0.0 |
Ambulatory Care | 2 | 6.0 |
